Skip to main content

Evonik announces ‘next phase of strategic transformation’

13th May 2022

Submitted by:

Andrew Warmington

At its Capital Markets Day, Evonik announced that it is embarking on the next phase of its strategic transformation. During this, said board chairman Christian Kullmann, the company will be “executing targeted and massive investments in green growth and making sustainability our central innovation driver”.

Evonik will focus on its three ‘growth divisions’ of Specialty Additives, Nutrition & Care and Smart Materials, while selling off Performance Materials. It aims to find new owners or partners for the division’s three businesses, Superabsorbents, Functional Solutions and Performance Intermediates, during 2023.

Performance Materials has sales of about €1.8 billion/year and accounts for about 12% of Evonik’s revenue. Last year, its adjusted EBITDA rose from €88 million to €136 million on the back of strong demand, but many of its products have become relatively commoditised. They include acrylic acid, oxo alcohols and plasticisers, potassium derivatives and intermediates for pharmaceuticals, cosmetics and surfactants.

The proceeds from the divestments and the operating cash flow in the coming years will be channelled to the green transformation, Kullmann added. By 2030, Evonik aims to invest more than €3 billion, 80% of its annual growth investments, to ‘Next Generation Solutions’, which offer sustainability benefits.

The company aims to increase the share of these products from 37% now to 50% by 2030. These include delivery technologies for controlled release of APIs, gas separation membranes and natural-based cosmetic active ingredients. In addition, the repositioned RD&I unit is “fully integrating sustainability into the management of Evonik’s innovation activities”.

A further €700 million will be invested in ‘Next Generation Technologies’, that is production processes and infrastructure to avoid CO2 emissions. Evonik is seeking to reduce its Scope 1 and 2 emissions by 25% from 6.5 million tonnes/year to 4.9 million by 2030. The investment will also help to cut operating costs by more than €100 million/year up to 2030.

As part of the transformation, Evonik has reviewed its mid-term financial targets and confirmed core targets of an adjusted EBITDA margin of 18-20%, a cash conversion rate of over 40% and ROCE of around 11%. In line with the full alignment to high-growth speciality chemicals, it will seek organic sales CAGR of over 4%, up from the previous target of 3% volume growth.

Earlier, Evonik’s Active Oxygens business line had released a new sustainability strategy for its hydrogen peroxide (H2O2), peracetic acid and persulfates. This includes steps to slash carbon emissions and increase resource efficiency in production, with the goal of achieving climate neutrality by 2040.

These products are powerful oxidants, which break down quickly into oxygen and water and as such are considered to be some of the cleanest chemicals available. However, conventional upstream production has a substantial carbon footprint. Demand for H2O2 is growing at 7-8%/year.

Plans involve increasing the proportion of renewable electricity in producing these chemicals from 80% in 2021 to 90% in 2023 and having a fully climate-neutral facility by 2032. New means will also be implemented for heat pumps and efficient energy reuse over the next ten years.

Active Oxygens is also pursuing plans to switch fossil-based raw materials in its production processes to bio-based acetic acid and green hydrogen among other things. It is currently exploring options to source sustainable hydrogen locally at each of its sites, with the first scheduled to use it in 2026.

Evonik has also opened its new ‘Agro Hub’ for its Interface & Performance business line in Americana, Sao Paulo, Brazil. This combines new laboratories, two pilot plants and infrastructure to support customer training. The business offers additives and adjuvants for conventional and biological agrochemical formulations under the Break-Thru brand. Existing tech centres are at Marl, Germany, and Richmond, Virginia.

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Halozyme has dropped its approach to buy Evotec

Halozyme abandons Evotec bid

San Diego-based biopharmaceutical company Halozyme Therapeutics has withdrawn the offer it made for Evotec after

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington